quinazolines has been researched along with Leukemia, Lymphoblastic, Acute, T Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, X; Huang, Y; Lin, L; Ma, X; Zou, Y | 1 |
| Accogli, T; Ballerini, P; Bastie, JN; Buffière, A; Delva, L; Lucchi, G; Pflumio, F; Quéré, R; Saint-Paul, L; Uzan, B | 1 |
| Barata, JT; Batista, A; Cardoso, AA; Carlesso, N; Nadler, LM; Raderschall, E; Sallan, SE | 1 |
| Guo, W; Huang, W; Kung, HJ; Lam, KS; Li, J; Liu, R; Ma, AH; Martinez, A; Maverakis, E; Mazloom, A; Ning, J; Ono, Y; Sanchez, E; Wang, Y | 1 |
4 other study(ies) available for quinazolines and Leukemia, Lymphoblastic, Acute, T Cell
| Article | Year |
|---|---|
Effect of BIX-01294 on proliferation, apoptosis and histone methylation of acute T lymphoblastic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Histones; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines | 2017 |
Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Disease Models, Animal; Humans; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Membrane Microdomains; Membrane Potential, Mitochondrial; Mice; Neoplastic Stem Cells; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2018 |
Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Topics: Antibiotics, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Dexamethasone; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Eukaryotic Initiation Factor-4G; Humans; Immunoblotting; Immunohistochemistry; Janus Kinase 3; Microscopy, Fluorescence; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Interferon-gamma; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Mice; Mice, Nude; MicroRNAs; Models, Molecular; Neoplasm Transplantation; Phosphorylation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinazolines; T-Lymphocytes; Transplantation, Heterologous; Up-Regulation | 2012 |